Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir

Antiviral Therapy

Volumn 16, Issue 5, 2011, Pages 695-704

  Hofmann, Wolf Peter ^a   Chung, Tje Lin ^b   Osbahr, Carola ^a   Susser, Simone ^a   Karey, Ursel ^a   Mihm, Ulrike ^a   Welsch, Christoph ^a,c   Loẗsch, Jor̈n ^a   Sarrazin, Christoph ^a   Zeuzem, Stefan ^a   Herrmann, Eva ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BOCEPREVIR; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HEPATITIS C VIRUS; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REPLICON; RNA ANALYSIS; VIRUS INHIBITION;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MODELS, THEORETICAL; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; REPLICON; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 80052511465     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1821     Document Type: Article

References (40)

1. Strader D.B., Wright T., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171. (Pubitemid 38428955)
2. Fattovich G., Stroffolini T., Zagni I., Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004; 127:S35-S50. (Pubitemid 39423368)
3. Veldt B.J., Heathcote E.J., Wedemeyer H., et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147:677-684. (Pubitemid 351664462)
4. Hoofnagle J.H., Seeff L.B. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355:2444-2451. (Pubitemid 44903748)
5. Manns M.P., Foster G.R., Rockstroh J.K., Zeuzem S., Zoulim F., Houghton M. The way forward in HCV treatment - Finding the right path. Nat Rev Drug Discov 2007; 6:991-1000. (Pubitemid 350201789)
6. Pawlotsky J.M., Chevaliez S., McHutchison J.G. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132:1979-1998. (Pubitemid 46695724)
7. Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre Phase 2 trial. Lancet 2010; 376:705-716.
8. Hézode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.
9. Pereira A.A., Jacobson I.M. New and experimental therapies for HCV. Nat Rev Gastroenterol Hepatol 2009; 6:403-411.
10. Bain V.G., Lee S.S., Peltekian K., et al. Clinical trial: Exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin. Aliment Pharmacol Ther 2008; 28:43-50. (Pubitemid 351782811)
11. Maynard M., Gagnieu M.C., Pradat P., Souvignet C., Trepo C. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther 2008; 13:607-611. (Pubitemid 352016724)
12. Loustaud-Ratti V., Alain S., Rousseau A., et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 2008; 47:1453-1461. (Pubitemid 351702729)
13. Sulkowski M., Shiffman M., Afdhal N., et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virological response rate. Gastroenterology 2010; 139:1602-1611.
14. Reddy K.R., Shiffman M.L., Morgan T.R., et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5:124-129. (Pubitemid 46096836)
15. Lohmann V., Korner F., Dobierzewska A., Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001; 75:1437-1449. (Pubitemid 32094702)
16. Hofmann W.P., Polta A., Herrmann E., et al. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology 2007; 132:921-930. (Pubitemid 46440857)
17. Berenbaum M.C. What is synergy? Pharmacol Rev 1989; 41:93-141. (Pubitemid 20019599)
18. Greco W.R., Bravo G., Parsons J.C. The search for synergy: A critical review from a response surface perspective. Pharmacol Rev 1995; 47:331-385.
19. Drusano G.L., D'Argenio D.Z., Symonds W., et al. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother 1998; 42:2153-2159. (Pubitemid 28420342)
20. Lin K., Kwong A.D., Lin C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother 2004; 48:4784-4792. (Pubitemid 39577685)
21. Prichard M.N., Shipman C., Jr. A three-dimensional model to analyze drug-drug interactions. Antiviral Res 1990; 14:181-205. (Pubitemid 20377558)
22. Coelmont L., Paeshuyse J., Windisch M.P., De Clercq E., Bartenschlager R., Neyts J. Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methylcytidine, the active component of valopicitabine. Antimicrob Agents Chemother 2006; 50:3444-3446. (Pubitemid 44527521)
23. Shiffman M.L. What future for ribavirin? Liver Int 2009; 29 Suppl 1:68-73.
24. Inoue Y., Homma M., Matsuzaki Y., et al. Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy. Hepatol Res 2006; 34:23-27. (Pubitemid 43091872)
25. Homma M., Matsuzaki Y., Inoue Y., et al. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirininduced anemia. Clin Gastroenterol Hepatol 2004; 2:337-339. (Pubitemid 38447199)
26. Paeshuyse J., Vliegen I., Coelmont L., et al. Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. Antimicrob Agents Chemother 2008; 52:3433-3437.
27. Wohnsland A., Hofmann W.P., Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007; 20:23-38. (Pubitemid 46167766)
28. Chung R.T., Gale M., Jr, Polyak S.J., Lemon S.M., Liang T.J., Hoofnagle J.H. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology 2008; 47:306-320. (Pubitemid 351171068)
29. Tanabe Y., Sakamoto N., Enomoto N., et al. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J Infect Dis 2004; 189:1129-1139. (Pubitemid 38457235)
30. Kato T., Date T., Miyamoto M., et al. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J Clin Microbiol 2005; 43:5679-5684. (Pubitemid 41612348)
31. Lin T.I., Lenz O., Fanning G., et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009; 53:1377-1385.
32. Feld J.J., Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436:967-972. (Pubitemid 41191673)
33. Hofmann W.P., Herrmann E., Sarrazin C., Zeuzem S. Ribavirin mode of action in chronic hepatitis C: From clinical use back to molecular mechanisms. Liver Int 2008; 28:1332-1343.
34. Feld J.J., Nanda S., Huang Y., et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007; 46:1548-1563. (Pubitemid 350155537)
35. Thomas E., Feld J.J., Li Q., Hu Z., Fried M.W., Liang T.J. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011; 53:32-41.
36. Vogt M.W., Hartshorn K.L., Furman P.A., et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987; 235:1376-1379. (Pubitemid 17041656)
37. Hernandez-Santiago B.I., Bassit L., Grier J., Schinazi R.F. Anti-HCV activity and cellular pharmacology of 2′-Cmethyl- cytidine alone and in combination with non-toxic concentrations of ribavirin in the HCV replicon system. Antivir Ther 2007; 12 Suppl 1:S28.
38. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138:447-462.
39. Mathy J.E., Ma S., Compton T., Lin K. Combinations of cyclophilin inhibitor NIM811 with hepatitis C virus NS3-4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother 2008; 52:3267-3275.
40. Coelmont L., Kaptein S., Paeshuyse J., et al. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother 2009; 53:967-976.